A Study of Aripiprazole in Patients With Major Depressive Disorder
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this 14 week, randomized, double-blind, placebo controlled study is to assess
the safety and efficacy of aripiprazole to placebo as adjunctive treatment to an assigned
open-label marketed antidepressant therapy (ADT) in patients with Major Depressive Disorder
who demonstrate an incomplete response to a prospective eight week trial of the same assigned
open-label marketed antidepressant therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.